Foresight Initiates First Dosing In Viral Conjunctivitis Clinical Trial
Foresight has reported the dosing of first patient in a viral conjunctivitis clinical trial. Foresight’s lead compound, FST-100, will be tested in a placebo-controlled, masked, and randomized multicenter
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.